CNBCSun, 31 May 2026 12:00:02 GMTWhy Trump reversed course to fast-track psychedelic drugs for mental healthcareCMPS-4.19%
Seeking AlphaWed, 27 May 2026 12:39:33 GMTCompass Pathways: A Trip Worth Taking Before The FDA VerdictCMPS-4.19%
MarketBeatThu, 21 May 2026 06:03:50 GMTCompass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 WinsCMPS-4.19%
Investors Business DailyMon, 18 May 2026 14:04:33 GMTThis Psychedelics Stock Just Keeps Getting Hotter; Why Shares Bypassed A Profit-Taking ZoneCMPS-4.19%
Seeking AlphaFri, 15 May 2026 00:36:14 GMTCompass Pathways: Imminent Commercialization Should Provide Further UpsideCMPS-4.19%
Seeking AlphaWed, 13 May 2026 20:00:50 GMTCOMPASS Pathways plc (CMPS) Q1 2026 Earnings Call TranscriptCMPS-4.19%
Investors Business DailyWed, 13 May 2026 16:34:36 GMTHere's Why This Psychedelics Stock Just Took A Trip To A Two-Year HighCMPS-4.19%
Zacks Investment ResearchFri, 24 Apr 2026 14:41:24 GMTIs COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year?CMPS-4.19%
Zacks Investment ResearchWed, 22 Apr 2026 17:01:25 GMTWhat Makes COMPASS Pathways PLC Sponsored ADR (CMPS) a Strong Momentum Stock: Buy Now?CMPS-4.19%
Zacks Investment ResearchWed, 22 Apr 2026 14:56:08 GMTHow Much Upside is Left in COMPASS Pathways (CMPS)? Wall Street Analysts Think 136%CMPS-4.19%
Seeking AlphaTue, 21 Apr 2026 15:45:00 GMTCompass Pathways: Red Hot Psychedelic Market For Pioneer With Near Term Psychedelic Filing In TRDCMPS-4.19%
MarketBeatMon, 20 Apr 2026 19:05:42 GMTThis 4/20, Wall Street Is Betting on More Than MarijuanaCMPS-4.19%
Seeking AlphaMon, 20 Apr 2026 15:26:58 GMTCompass Pathways: The Bull Case Is Early, Not WrongCMPS-4.19%
